icone plus
Contact Abonnez-vous aux actualités
Reason for request
Extension of indication
Clinical Benefit
Clinical Added Value
no clinical added value
EYLEA does not provide any improvement in actual benefit (level V, non-existent) compared with LUCENTIS for adults in the treatment of visual impairment due to macular oedema secondary to central retinal vein occlusion (CRVO).
eNq1mFFv2jAQx9/5FFHeSQhbFzYFqo21G9KqMVq0aS+VSY5i5trp2aawTz+H0I1Ojtoa/Bjb+d/F9/fPp2Sn61sWrAAlFbwfJlEnDIDnoqD8ph9Or87bvfB00MqWZEX2lqVRJ0q6YZAzImU/rGajGRAuox8XXz6CeR8wHLSCTMyWkKtH67SiLPpM5OKClNWaIFsJWgS3oBai6IelVtvRIJMKTRaDe4G/ZElyyOLdyP7s8vr1/ngWV2LPUNUS8AvhN1ZR4E6auUYEroZEwY3ATUO+r5y0qZyAFBpzGBO1GKNY0QIKa4g5YRKcgszvi0vAFQNVBbGKx8v8VjqJkyVZT+BuZE/6vZkdqrVqd9pJetLt9pK0l6adrlMo3NsqexXMR8T5tYmUJGkaA49hw4A4VmYsUBHmqSZUDh/bylMchLsna19QWTKyiZaydN0qgsRMA5rD7+9Dqi+4QoMjZvbsP32uGYtfmPV0BwtPGVcsGgrNVQMzzieuGzEUXMG6uaJumFPrnRcpyOPJ/hbcjvixnjGauwLNIEeDVNPJqJlnx0PBByJhiv5Y8J3yQtzL4zNmv6aesi+3mLSKllgk1923vTfJyYnzEfppDNRwu5xpFCXEhj5UHgKVEZ+LQ3FiPGmXenDkkcy47XBEThg09DhtR64YFz60ZN587u8M1RNW0U9nV67m+KYBN5fbR6s0Lfp/y+oGXR8kN1ZsTPzlxq7Pt5fuV6OdGwulSvkujhdEtiUxOxTN8chE37tC/XXdXu7pum+pqegp9Vl93T2/Nq7n66lb/NDOdPf+rgO2xlCo4YA61Cj2BszR2fEZ/K8t9Zb2+BEz/IXZtpBEUcF9NTd6ZlU8jPqmrvwcDRy+zue04Q9Ioy+zuP77MmhlcfXnZdD6Awa73hc=
8hGXN4geJbDbJsuW
Listen
